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Supplemental Table 1. TRIPOD Checklist 
Section/Topic Item  Checklist Item Page 
Title and abstract 
Title 1 D;V 
Identify the study as developing and/or validating a multivariable prediction model, the 
target population, and the outcome to be predicted. 
1 
Abstract 2 D;V 
Provide a summary of objectives, study design, setting, participants, sample size, 
predictors, outcome, statistical analysis, results, and conclusions. 
2 
Introduction 
Background 
and objectives 
3a D;V 
Explain the medical context (including whether diagnostic or prognostic) and rationale 
for developing or validating the multivariable prediction model, including references to 
existing models. 
3 
3b D;V 
Specify the objectives, including whether the study describes the development or 
validation of the model or both. 
3 
Methods 
Source of data 
4a D;V 
Describe the study design or source of data (e.g., randomized trial, cohort, or registry 
data), separately for the development and validation data sets, if applicable. 
4 
4b D;V 
Specify the key study dates, including start of accrual; end of accrual; and, if applicable, 
end of follow-up.  
4 
Participants 
5a D;V 
Specify key elements of the study setting (e.g., primary care, secondary care, general 
population) including number and location of centres. 
4 
5b D;V Describe eligibility criteria for participants.  4 
5c D;V Give details of treatments received, if relevant.  4 
Outcome 
6a D;V 
Clearly define the outcome that is predicted by the prediction model, including how and 
when assessed.  
4-5 
6b D;V Report any actions to blind assessment of the outcome to be predicted.  N.A. 
Predictors 
7a D;V 
Clearly define all predictors used in developing or validating the multivariable prediction 
model, including how and when they were measured. 
4-5 
7b D;V 
Report any actions to blind assessment of predictors for the outcome and other 
predictors.  
N.A. 
Sample size 8 D;V Explain how the study size was arrived at. N.A. 
Missing data 9 D;V 
Describe how missing data were handled (e.g., complete-case analysis, single 
imputation, multiple imputation) with details of any imputation method.  
5. 
Statistical 
analysis 
methods 
10a D Describe how predictors were handled in the analyses.  N.A. 
10b D 
Specify type of model, all model-building procedures (including any predictor selection), 
and method for internal validation. 
5 
10c V For validation, describe how the predictions were calculated.  5 
10d D;V 
Specify all measures used to assess model performance and, if relevant, to compare 
multiple models.  
5-6 
10e V Describe any model updating (e.g., recalibration) arising from the validation, if done. N.A. 
Risk groups 11 D;V Provide details on how risk groups were created, if done.  5 
Development 
vs. validation 
12 V 
For validation, identify any differences from the development data in setting, eligibility 
criteria, outcome, and predictors.  
N.A. 
Results 
Participants 
13a D;V 
Describe the flow of participants through the study, including the number of participants 
with and without the outcome and, if applicable, a summary of the follow-up time. A 
diagram may be helpful.  
6. 
13b D;V 
Describe the characteristics of the participants (basic demographics, clinical features, 
available predictors), including the number of participants with missing data for 
predictors and outcome.  
6 
13c V 
For validation, show a comparison with the development data of the distribution of 
important variables (demographics, predictors and outcome).  
N.A. 
Model 
development  
14a D Specify the number of participants and outcome events in each analysis.  6 
14b D 
If done, report the unadjusted association between each candidate predictor and 
outcome. 
Supplemental 
Table 2 
Model 
specification 
15a D 
Present the full prediction model to allow predictions for individuals (i.e., all regression 
coefficients, and model intercept or baseline survival at a given time point). 
6 
15b D Explain how to the use the prediction model. 10 
Model 
performance 
16 D;V Report performance measures (with CIs) for the prediction model. 
6 and Figure 1 
and 2 
Model-updating 17 V 
If done, report the results from any model updating (i.e., model specification, model 
performance). 
N.A. 
Discussion 
Limitations 18 D;V 
Discuss any limitations of the study (such as nonrepresentative sample, few events per 
predictor, missing data).  
10 
Interpretation 
19a V 
For validation, discuss the results with reference to performance in the development 
data, and any other validation data.  
9 
19b D;V 
Give an overall interpretation of the results, considering objectives, limitations, results 
from similar studies, and other relevant evidence.  
8-10 
Implications 20 D;V Discuss the potential clinical use of the model and implications for future research.  8-10 
Other information 
Supplementary 
information 
21 D;V 
Provide information about the availability of supplementary resources, such as study 
protocol, Web calculator, and data sets.  
N.A 
Funding 22 D;V Give the source of funding and the role of the funders for the present study.  N.A. 
   Supplemental Table 2. Baseline clinical characteristics of patients in the validation and 
development cohorts 
  SWISS TAVI Registry STS/ACC TVT Registry 
  n= 3491 n= 13718 
Age (years) 82.1 ±  6.5 82.1 ±  8.3 
Male gender (%) 1760 (50%) 6680 (48.7%) 
Values are mean ± SD or percentages.
     Supplemental Table 3. Type and frequency of transcatheter heart 
valves in the Swiss TAVI cohort 
  All patients Survivors Died in hospital 
  n= 3,491 n= 3,390 n= 101 
Medtronic CoreValve 917 (26%) 892 (26%) 25 (25%) 
Edwards Sapien XT 606 (17%) 582 (17%) 24 (24%) 
Symetis Acurate 98  (3%) 96  (3%) 2  (2%) 
JenaValve 57  (2%) 53  (2%) 4  (4%) 
SJM Portico 87  (3%) 85  (3%) 2  (2%) 
Medtronic Engager 2  (0%) 1  (0%) 1  (1%) 
Direct Flow Medical 34  (1%) 33  (1%) 1  (1%) 
Edwards Sapien 3 1163 (33%) 1131 (33%) 32 (32%) 
BSC Lotus 186  (5%) 186  (6%) 0  (0%) 
Medtronic Evolut R 330  (9%) 321  (9%) 9  (9%) 
 Refitted coefficients are shown for descriptive purpose only. Original coefficients were used to assess 
the predictive performance of the TVT Registry model in the external validation cohort. Missing data 
was imputed using chained equations to generate 20 imputations sets. Estimates were combined using 
Rubin's rule.  No acuity category 3 patients defined. eGFR, Estimated glomerular filtration rate; NYHA, 
New York Heart Association. 
 
 
 
 
 
 
 
 
 
Supplemental Table 4. Univariable and multivariable predictors of mortality rates from the external 
validation cohort 
  
Unadjusted  
OR (95% CI) 
p 
value 
  
Adjusted  
OR (95% CI) 
p 
value 
 
In-hospital mortality 
          
Age (5 year intervals) 1.36 (1.13 - 1.63) 0.001   1.41 (1.16 - 1.71) 0.001 
GFR (5-U increments) 0.91 (0.87 - 0.95) <0.001   0.92 (0.87 - 0.98) 0.005 
Dialysis 1.77 (0.64 - 4.94) 0.27   1.20 (0.38 - 3.79) 0.76 
NYHA class IV 1.60 (0.94 - 2.73) 0.083   1.04 (0.58 - 1.89) 0.89 
Severe chronic lung disease 1.20 (0.69 - 2.10) 0.52   1.30 (0.73 - 2.33) 0.37 
Non femoral access 2.59 (1.65 - 4.07) <0.001   2.97 (1.86 - 4.73) <0.001 
Acuity category 2 3.08 (1.39 - 6.85) 0.006   3.25 (1.41 - 7.52) 0.006 
Acuity category 4 6.04 (2.29 - 15.93) <0.001   6.20 (1.90 - 20.24) 0.003 
            
30 day mortality           
Age (5 year intervals) 1.34 (1.14 - 1.58) <0.001   1.39 (1.17 - 1.64) <0.001 
GFR (5-U increments) 0.89 (0.85 - 0.93) <0.001   0.90 (0.86 - 0.95) <0.001 
Dialysis 2.08 (0.89 - 4.87) 0.091   1.15 (0.44 - 3.03) 0.78 
NYHA class IV 1.39 (0.85 - 2.26) 0.191   0.79 (0.45 - 1.38) 0.40 
Severe chronic lung disease 1.31 (0.81 - 2.11) 0.27   1.47 (0.89 - 2.41) 0.13 
Non femoral access 2.48 (1.66 - 3.72) <0.001   2.80 (1.85 - 4.25) <0.001 
Acuity category 2 2.30 (1.04 - 5.07) 0.04   2.45 (1.07 - 5.63) 0.034 
Acuity category 4 8.27 (3.67 - 18.64) <0.001   8.56 (3.06 - 23.89) <0.001 
      
 Supplemental Table 5. Performance of the TVT Registry Model across different 
time periods 
  AUC (95% CI) χ²* p value* 
November 2011- February 2014 (N = 1317) 
In-hospital death 0.68 (0.59 - 0.76) 11.51 0.174 
30 day death 0.68 (0.61 - 0.75) 7.59 0.475 
March 2014-February 2016 (N = 2174) 
In-hospital death 0.63 (0.54 -0.71) 4.2 0.839 
30 day death 0.66 (0.59 - 0.73) 2.97 0.936 
November 2011- February 2014 corresponds to the same time period of the derivation cohort.  *Hosmer-Lemeshow test. 
**Combination of Chi² statistics in MI result in values from an F distribution. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
Supplemental Table 6. Model fit statistics after multiple 
imputation of missing variables  
         
   AUC (95% CI) 
 
p value* 
         
 TVT Registry Model       
 In-hospital mortality 0.66 (0.60 - 0.71)   0.25 
 30-day mortality 0.68 (0.63 - 0.73)   0.46 
     
STS-PROM score   
  In-hospital mortality 0.61 (0.56 - 0.67)   0.63 
 30-day mortality 0.64 (0.59 - 0.68)   0.56 
 Combination of Chi² statistics in MI result in values from an F distribution. 
*Hosmer-Lemeshow test. The following variables were imputed: age(0.26% of 
cases), estimated glomerular  filtration rate (0.43%), dialysis (0.11%), NYHA class 
4 (2.21%). 
 
  
 
